Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Int J Clin Exp Pathol. 2012;5(5):397-410. Epub 2012 May 23.

ALK-immunoreactive neoplasms.

Author information

  • 1Department of Pathology, University of California San Diego Health Sciences System, La Jolla, CA 92093-0987, USA.

Abstract

CONTEXT:

Since the first discovery of anaplastic lymphoma kinase (ALK) in anaplastic large cell lymphoma (ALCL) by Morris et al in 1994, the number of ALK-positive neoplasms, either in the form of translocation or gain-of-function mutations, have been dramatically expanded from ALCL of T- and NK-cell origin, to diffuse large B-cell lymphoma, inflammatory myofibroblastic tumor (IMT), neuroblastoma, non-small cell lung carcinoma (NSCLC), undifferentiated anaplastic thyroid carcinoma, and rare type of sarcomas.

OBJECTIVE:

This review covers the major aspects of ALK-immunoreactive neoplasms with emphasis on the pathogenesis of ALK-positive neoplasms. The new advances and rapid-evolving practices using ALK inhibitors for therapy are also discussed at the end of this review.

DATA SOURCES:

ALK(+) articles published in English literature are retrieved and critically reviewed.

CONCLUSION:

ALK(+) neoplasia is a rapidly growing field and the list of ALK(+) neoplasms is being expanded continuously. Accurate and correct diagnosis of ALK(+) neoplasms is of paramount importance in guiding the appropriate treatment in the era of personalized medicine using specific ALK inhibitor.

KEYWORDS:

ALK-positive neoplasms; Anaplastic lymphoma kinase (ALK); anaplastic large cell lymphoma (ALCL)

PMID:
22808292
[PubMed - indexed for MEDLINE]
PMCID:
PMC3396068
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk